Brenda Gavin
Managing Partner, Quaker BioVentures
Dr. Gavin is a founding partner of Quaker BioVentures. Previously, she was President of S.R. One, Limited (S.R.
One), GlaxoSmithKline's bioscience venture capital investment company, and a general partner of EuclidSR Partners,
an independent venture capital limited partnership focused on healthcare, information technology, and their
convergence. Since its inception in 1985, S.R. One has invested over $340 million in approximately 100 life sciences
companies and 20 venture funds. Dr. Gavin was responsible for many of the direct venture and strategic investments
made by S.R. One. She served as a board member or active board observer for many of these, including Adolor, Inhale,
Sepracor and Versicor.
Prior to joining S.R. One in 1989, Dr. Gavin was Director of Business Development for SmithKline Beecham Animal
Health Products. She started her career as an epidemiologist at the Centers for Disease Control and Prevention.
Dr. Gavin is a graduate of Baylor University where she majored in Biology. She received her Doctor of Veterinary
Medicine from the University of Missouri and her Master of Business Administration from the University of Texas -
San Antonio. Dr. Gavin is highly regarded in the venture capital community and is a board member of Eximias
Pharmaceutical Corporation, Celator Pharmaceuticals, Inc, the Ben Franklin Technology Center of Southeastern
Pennsylvania, the Ben Franklin Technology Development Authority, Innovation Philadelphia, BioAdvance (the
Biotechnology Greenhouse Corporation of Southeastern Pennsylvania), and serves on the advisory boards of the
Pennsylvania State University Research Foundation and the Monell Institute. Dr. Gavin is a past board member of the
National Venture Capital Association and she is also an active board observer of Nucleonics Inc.
